GSK plc announced the commencement of a tender offer to acquire Nuvalent, Inc., the Cambridge-based precision oncology company, at $78.00 per share in cash. The transaction values Nuvalent at approximately $6.8 billion on a fully diluted basis. The offer represents a 38% premium to Nuvalent's closing price on the last trading day prior to initial acquisition discussions. GSK expects to fund the acquisition through existing cash resources and committed credit facilities.

Nuvalent's portfolio centers on three clinical-stage kinase inhibitors targeting genomically defined subsets of non-small cell lung cancer and advanced solid tumors. The lead asset, zidesamtinib, is enrolling in Phase 2 trials for ROS1-positive and ALK-positive NSCLC, with interim data expected in the second half of 2025. The second program, NVL-655, addresses ALK resistance mutations that emerge after first-line tyrosine kinase inhibitor therapy. The third candidate, NVL-330, targets HER2-mutant cancers and remains in early-stage development. GSK disclosed that Nuvalent's current cash runway extends into mid-2026, providing operational continuity through key data readouts.

The acquisition fills a gap in GSK's oncology strategy, which has historically focused on synthetic lethality and immune-oncology mechanisms rather than targeted kinase inhibition. GSK's oncology revenue reached $2.1 billion in 2024, representing 6% of total company sales, trailing peers with more mature oncology franchises. The Nuvalent deal follows GSK's $1.9 billion acquisition of Sierra Oncology in 2022, which brought the JAK2 inhibitor momelotinib to market. With zidesamtinib's Phase 2 trials enrolling across multiple geographies, GSK gains potential access to a market segment where competitors including Pfizer, Roche, and Takeda have established positions but face emerging resistance challenges. ROS1-positive NSCLC affects approximately 2% of NSCLC patients globally, translating to roughly 40,000 new diagnoses annually in major markets.

The tender offer remains subject to customary closing conditions, including regulatory clearance under Hart-Scott-Rodino and foreign investment review in jurisdictions where Nuvalent maintains clinical trial sites. GSK expects to complete the transaction in the third quarter of 2025. Operators should monitor two near-term events: the June ASCO presentation, where Nuvalent is scheduled to disclose updated efficacy and safety data from the zidesamtinib Phase 2 cohort, and the FTC's second request timeline, which typically extends 30 to 45 days beyond initial filing. Any delay in the tender closing would expose GSK to execution risk if interim trial data underperforms consensus efficacy benchmarks.

GSK shares traded down 1.2% in London on the announcement, reflecting investor concern over capital allocation after the company committed $3.8 billion to dividend payments and $2.1 billion to share buybacks in 2024. The Nuvalent acquisition consumes roughly 22% of GSK's year-end cash position of $30.7 billion, leaving the balance sheet with modest leverage but reduced flexibility for additional near-term deals. The company's next earnings call on May 1 will provide updated guidance on oncology revenue contribution assumptions and any adjustments to capital deployment priorities through 2026.